Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure : a phase II randomized selection trial
スポンサーリンク
概要
- 論文の詳細を見る
- 2011-07-01
著者
-
KIM Sung-Bae
Department of Medicine, Asan Medical Center, University of Ulsan
-
Chung Hyun
Cancer Metastasis Research Center
-
Kim Sung-bae
Department Of Oncology Asan Medical Center University Of Ulsan College Of Medicine
-
Pen Daniel
Eli Lilly Lacmass
-
Xu Binghe
Department Of Medical Oncology Cancer Hospital Chinese Academy Of Medical Sciences And Peking Union
-
JIANG Zefei
Breast Cancer Department, 307 Hospital
-
YU Shiying
Cancer Center of Tongji Hospital, Huazhong University of Science and Technology
-
FENG Jifeng
Department of Oncology, Jiangsu Province Cancer Hospital
-
MALZYNER Artur
Department of Oncology, Hospital Brigadeiro
-
DEL GIGLIO
Department of Oncology, Faculdade de Medicina da Fundacao ABC
-
SHEN Li
Intercontinental Information Sciences, Eli Lilly China
-
Feng Jifeng
Department Of Oncology Jiangsu Province Cancer Hospital
-
Malzyner Artur
Department Of Oncology Hospital Brigadeiro
-
Del Giglio
Department Of Oncology Faculdade De Medicina Da Fundacao Abc
-
Chung Hyun
Cancer Metastasis Research Center Yonsei Cancer Center Yonsei University College Of Medicine
-
Yu Shiying
Cancer Center Of Tongji Hospital Huazhong University Of Science And Technology
-
Shen Li
Intercontinental Information Sciences Eli Lilly China
-
Jiang Zefei
Breast Cancer Department 307 Hospital
関連論文
- Comparison of Microvessel Density before and after Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients and Its Clinical Implications : Multicenter Trial
- A weighted sample size for microarray datasets that considers the variability of variance and multiplicity(BIOINFORMATICS)
- Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression
- Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure : a phase II randomized selection trial
- Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer